PBYI Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
55.1M
-2.6%
56.5M
+26.1%
44.8M
-40.6%
75.5M
+38.5%
54.5M
Cost of Revenue
15.2M
+21.8%
12.5M
+19.7%
10.4M
-54.9%
23.1M
+90.0%
12.2M
Gross Profit
39.9M
-9.5%
44.0M
+28.0%
34.4M
-34.3%
52.3M
+23.7%
42.3M
Operating Expenses
34.6M
-5.1%
36.4M
-4.6%
38.2M
+8.5%
35.2M
+7.6%
32.7M
R&D
18.3M
-3.2%
18.9M
-4.5%
19.8M
+17.5%
16.8M
+5.8%
15.9M
SG&A
16.3M
-7.1%
17.5M
-4.8%
18.4M
+0.2%
18.4M
+9.3%
16.8M
Operating Income
5.3M
-30.5%
7.6M
+298.1%
-3828000
-122.4%
17.1M
+78.7%
9.6M
EBITDA
7.7M
-23.5%
10.1M
+912.0%
-1244000
-106.3%
19.8M
+60.7%
12.3M
Net Income
6.0M
-27.3%
8.2M
+318.2%
-3753000
-127.9%
13.4M
+51.9%
8.8M
EPS (Basic)
$0.12
-25.0%
$0.16
+328.6%
$-0.07
-125.9%
$0.27
+50.0%
$0.18
EPS (Diluted)
$0.11
-31.3%
$0.16
+328.6%
$-0.07
-126.9%
$0.26
+52.9%
$0.17
Shares (Diluted)
53.1M
+1.0%
52.6M
+3.4%
50.8M
-1.5%
51.6M
+1.4%
50.9M
PUMA BIOTECHNOLOGY (PBYI) — Financials